In conclusion, this first prospective study of the Dutch JDM population supports the use of IFN-induced biomarkers Galectin-9 and CXCL10 and whole-body MRI in JDM diagnostics. This evidence concerns the gene CXCL10 and juvenile dermatomyositis.